A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores

BMC Pharmacology

Volumn 8, Issue , 2008, Pages

  Boik, John C ^a   Newman, Robert A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE P; BAICALEIN; BETA GALACTOSIDASE; CURCUMIN; CYCLIN DEPENDENT KINASE 2; CYTOTOXIC AGENT; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; GLUTATHIONE TRANSFERASE; JUGLONE; LUTEOLIN; MENADIONE; PHOSPHODIESTERASE V; PLUMBAGIN; QUERCETIN; RHEIN; URIDINE DIPHOSPHATE GLUCOSE 4 EPIMERASE; ANTINEOPLASTIC AGENT; PROTEIN;

ACCURACY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CLASSIFICATION MODEL; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; BIOLOGICAL MODEL; CLASSIFICATION; DRUG ANTAGONISM; EVALUATION; METABOLISM; PROTEIN BINDING; REPRODUCIBILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG ANTAGONISM; DRUG SYNERGISM; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 51049119630     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-8-13     Document Type: Article

References (33)

1. DeVita VT Jr. Canellos GP Moxley JH 3rd A decade of combination chemotherapy of advanced Hodgkin's disease Cancer 1972, 30(6):1495-1504 10.1002/1097-0142(197212)30:6<1495::AID-CNCR2820300613>3.0.CO;2-I 4565815
2. Goldin A Venditti JM Mantel N Kline I Gang M Evaluation of combination chemotherapy with three drugs Cancer Res 1968, 28(5):950-960 5652309
3. Boik JC Newman RA Boik RJ Quantifying synergism/antagonism using nonlinear mixed-effects modeling: A simulation study Statistics in Medicine 2008, 27(7):1040-1061 10.1002/sim.3005 17768754
4. Sheridan RP The centroid approximation for mixtures: Calculating similarity and deriving structure - activity relationships J Chem Inf Comput Sci 2000, 40(6):1456-1469 10.1021/ci000045j 11128105
5. Warren GL Andrews CW Capelli AM Clarke B LaLonde J Lambert MH Lindvall M Nevins N Semus SF Senger S Tedesco G Wall ID Woolven JM Peishoff CE Head MS A critical assessment of docking programs and scoring functions J Med Chem 2006, 49(20):5912-5931 10.1021/jm050362n 17004707
6. Perola E Minimizing false positives in kinase virtual screens Proteins 2006, 64(2):422-435 10.1002/prot.21002 16708364
7. Zsoldos Z Reid D Simon A Sadjad BS Johnson AP eHiTS: An innovative approach to the docking and scoring function problems Curr Protein Pept Sci 2006, 7(5):421-435 10.2174/138920306778559412 17073694
8. Akula N Lecanu L Greeson J Papadopoulos V 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA Bioorg Med Chem Lett 2006, 16(24):6277-6280 10.1016/j.bmcl.2006.09.030 17049234
9. Hayashi Y Sakaguchi K Kobayashi M Kobayashi M Kikuchi Y Ichiishi E Molecular evaluation using in silico protein interaction profiles Bioinformatics 2003, 19(12):1514-1523 10.1093/bioinformatics/btg189 12912832
10. Araujo RP Liotta LA Petricoin EF Proteins, drug targets and the mechanisms they control: The simple truth about complex networks Nature reviews 2007, 6(11):871-880 10.1038/nrd2381 17932492
11. Zimmermann GR Lehar J Keith CT Multi-target therapeutics: When the whole is greater than the sum of the parts Drug Discov Today 2007, 12(1-2):34-42 10.1016/j.drudis.2006.11.008 17198971
12. Lehar J Zimmermann GR Krueger AS Molnar RA Ledell JT Heilbut AM Short GF 3rd Giusti LC Nolan GP Magid OA Lee MS Borisy AA Stockwell BR Keith CT Chemical combination effects predict connectivity in biological systems Mol Syst Biol 2007, 3:80 1828746 17332758 10.1038/msb4100116
13. Carlson BA Dubay MM Sausville EA Brizuela L Worland PJ Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res 1996, 56(13):2973-2978 8674031
14. Safra T Cardiac safety of liposomal anthracyclines Oncologist 2003, 8(Suppl 2):17-24 10.1634/theoncologist.8-suppl_2-17 13679592
15. Tabata M Kiura K Okimoto N Segawa Y Shinkai T Yonei T Kuyama S Harita S Hotta K Ueoka H Tanimoto M A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer Cancer Chemother Pharmacol 2007, 60(1):1-6 10.1007/ s00280-006-0336-0 17393168
16. Patlakas G Bouros D Tsantekidou-Pozova S Koukourakis MI Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer Anticancer Res 2005, 25(2B):1427-1431 15865101
17. Nabholtz JM Tonkin K Smylie M Mackey J Janowska-Wieczorek A Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: From metastatic to adjuvant setting Semin Oncol 1999, 26(1 Suppl 3):10-16 10203265
18. Muggia FM Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers Drugs 1997, 54(Suppl 4):22-29 9361958
19. Boik JC Newman RA Structure-activity models of oral clearance, cytotoxicity, and LD50: A screen for promising anticancer compounds BMC Pharmacol 2008, 8:12 2442056 18554402 10.1186/1471-2210-8-12
20. DTP Human Tumor Cell Line Screen http://dtp.nci.nih.gov/index.html
21. Abas F Hui LS Ahmad S Stanslas J Israf DA Shaari K Lajis NH Biological evaluation of curcumin and related diarylheptanoids Z Naturforsch [C] 2006, 61(9-10):625-631 17137104
22. Lao CD Ruffin MT Normolle D Heath DD Murray SI Bailey JM Boggs ME Crowell J Rock CL Brenner DE Dose escalation of a curcuminoid formulation BMC complementary and alternative medicine 2006, 6:10 10.1186/1472-6882-6-10
23. The Comprehensive R Archive Network http://cran.r-project.org/
24. Python http://www.python.org/
25. Scipy http://www.scipy.org/
26. RCSB Protein Data bank http://www.rcsb.org/pdb/home/home.do
27. Dragon http://www.talete.mi.it/
28. Xiang Z Bennett KP Inductive transfer using kernel multitask latent analysis http://iitrl.acadiau.ca/itws05/Papers/ ITWS17-XiangBennett_REV.pdf
29. Momma M Bennett KP Constructing Orthogonal Latent Features for Arbitrary Loss Feature extraction: Foundations and applications New York, NY, Springer Berlin Heidelberg Guyon I, Gunn S, Nikravesh M, Zadeh L 2007
30. Hoskuldsson A PLS regression methods Journal of Chemometrics 1988, 2:211-228 10.1002/cem.1180020306
31. Boulesteix AL PLS dimension reduction for classification with microarray data Stat Appl Genet Mol Biol 2004, 3 1 Article33 16646813
32. Hastie T Tibshirani R Friedman J The elements of statistical learning New York, Springer-Verlag 2001
33. Dietterich TG Approximate statistical tests for comparing supervised classification learning algorithms Neural Comput 1998, 10(7):1895-1923 10.1162/089976698300017197 9744903